Fig. 9

Flow cytometry analysis of CD14⁺CD169⁺IRF7⁺ monocytes in SLE patients. (a) Flow cytometric gating strategies for CD14⁺CD169⁺ monocytes in healthy controls and two groups of SLE patients. (b) The frequency of CD14⁺CD169⁺IRF7⁺ cells under CD14⁺ gating strategy in healthy controls and two groups of SLE patients. (c) The frequency of CD14⁺CD169⁺/CD14⁺ monocytes in healthy controls (n = 10) and SLE patients (n = 31). (d) The frequency of CD14⁺CD169⁺/CD14⁺ monocytes in healthy controls and SLE patients with SLEDAI > 10 (n = 18) and SLEDAI ≤ 10 (n = 13). (e) The frequency of CD14⁺CD169⁺IRF7⁺/CD14⁺ monocytes in healthy controls and SLE patients. (f) The frequency of CD14⁺CD169⁺IRF7⁺/CD14⁺ monocytes in healthy controls and two groups of SLE patients. (ns p > 0.05, *p < 0.05, ***p < 0.001, ****p < 0.0001)